Wedbush Reaffirms “Buy” Rating for Millendo Therapeutics (NASDAQ:MLND)

Wedbush reaffirmed their buy rating on shares of Millendo Therapeutics (NASDAQ:MLND) in a report released on Thursday, AnalystRatings.com reports. The brokerage currently has a $24.00 price target on the stock. Wedbush also issued estimates for Millendo Therapeutics’ Q4 2019 earnings at ($1.01) EPS, FY2019 earnings at ($3.45) EPS and FY2020 earnings at ($3.52) EPS.

A number of other brokerages have also commented on MLND. Zacks Investment Research raised shares of Millendo Therapeutics from a sell rating to a hold rating in a research report on Tuesday, July 16th. Oppenheimer reduced their target price on shares of Millendo Therapeutics from $26.00 to $25.00 and set an outperform rating on the stock in a research report on Tuesday, August 13th. CIBC began coverage on shares of Millendo Therapeutics in a research report on Tuesday, July 16th. They set an outperform rating and a $26.00 target price on the stock. ValuEngine raised shares of Millendo Therapeutics from a hold rating to a buy rating in a research report on Thursday, August 1st. Finally, Citigroup began coverage on shares of Millendo Therapeutics in a research report on Monday, July 15th. They set an outperform rating and a $26.00 target price on the stock. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Millendo Therapeutics presently has an average rating of Buy and an average target price of $22.97.

Millendo Therapeutics stock opened at $6.98 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.90 and a quick ratio of 7.83. Millendo Therapeutics has a 1-year low of $6.63 and a 1-year high of $17.34. The company’s 50-day moving average is $10.18 and its 200 day moving average is $13.06.

Millendo Therapeutics (NASDAQ:MLND) last issued its earnings results on Monday, August 12th. The company reported ($0.74) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.07. On average, equities research analysts anticipate that Millendo Therapeutics will post -3.22 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in shares of Millendo Therapeutics by 1,738.4% during the second quarter. BlackRock Inc. now owns 468,342 shares of the company’s stock valued at $5,414,000 after purchasing an additional 442,866 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Millendo Therapeutics by 62.2% during the second quarter. Vanguard Group Inc. now owns 331,285 shares of the company’s stock valued at $3,829,000 after purchasing an additional 126,994 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Millendo Therapeutics by 100.3% during the second quarter. Renaissance Technologies LLC now owns 208,864 shares of the company’s stock valued at $2,414,000 after purchasing an additional 104,567 shares in the last quarter. International Biotechnology Trust PLC boosted its stake in shares of Millendo Therapeutics by 187.5% during the second quarter. International Biotechnology Trust PLC now owns 177,825 shares of the company’s stock valued at $2,056,000 after purchasing an additional 115,965 shares in the last quarter. Finally, AWM Investment Company Inc. boosted its stake in shares of Millendo Therapeutics by 288.1% during the second quarter. AWM Investment Company Inc. now owns 77,629 shares of the company’s stock valued at $897,000 after purchasing an additional 57,629 shares in the last quarter. Hedge funds and other institutional investors own 44.03% of the company’s stock.

Millendo Therapeutics Company Profile

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Further Reading: What are the benefits of momentum investing?

Analyst Recommendations for Millendo Therapeutics (NASDAQ:MLND)

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.